ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, and BodeVet, a Maryland-based company focused on the development of novel blood products for use in veterinary transfusion and regenerative medicine, have announced a joint effort to significantly expand the availability of ELIAS’ ECI® treatment for canine cancer via the mobile apheresis capabilities of BodeVet.
Apheresis is a processing procedure that separates blood into different components and, in this case, yields the T cells critical to the ELIAS treatment protocol. Currently, there are twelve locations offering apheresis for pets. BodeVet offers a mobile service that will enable veterinary oncologists in most major cities in the United States to incorporate ECI® into their specialty hospital portfolio of oncology services, expanding beyond chemotherapy and radiation.
Working together, ELIAS and BodeVet are committed to promoting animal health and welfare by developing and delivering new treatment solutions to veterinary medical practitioners.
“We are very excited to work with BodeVet to make this new cancer treatment option accessible to more veterinarians,” said Tammie Wahaus, CEO of ELIAS. “Using a mobile service greatly enhances the convenience for both clinicians and pet owners. This will enable ECI® to become a treatment option for oncologists across the United States sooner than might otherwise be possible.”
BodeVet, a wholly owned subsidiary of Cellphire, Inc., is solving the unmet needs of companion and exotic animals for transfusion medicine and regenerative therapies. The company launched its first commercial product, StablePlateRX Canine, a freeze-dried hemostatic agent derived from canine platelets in 2017. Built on a socially-responsible sourcing, cGMP manufacturing, and product consistency, BodeVet helps the veterinary community provide more predictable and favorable outcomes. To learn more, visit www.bodevet.com.
About ELIAS Animal Health
Based in Olathe, Kan., ELIAS Animal Health is a medical biotechnology company advancing its novel targeted T cell-based immunotherapies for the treatment of canine cancers. The ELIAS cancer immunotherapy, an autologous prescription product, is being distributed to veterinarians under 9 CFR 103.3 as an experimental product. Efficacy and safety have not been established. The company’s novel therapeutic approach offers the promise of improved clinical outcomes and the potential for fundamentally changing the way cancer is treated.
#LIVESTOCK #POULTRY #AQUACULTURE #MIDDLEEAST #LIVESTOCKMAGAZINE #POULTRYMAGAZINE